文献速递流行病学与生物统计组学、生物样本库与精准医学新药、器械与细胞基因治疗研发

非洲与南亚致新生儿败血症肺炎克雷伯菌的荚膜与O型分布:基于基因组预测血清型流行率的Meta分析以指导潜在疫苗覆盖

Distribution of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and South Asia: A meta-analysis of genome-predicted serotype prevalence to inform potential vaccine coverage.
PubMed 文献 · PLoS Med · 2026-01-12

该Meta分析纳入13国35个监测点1930株新生儿血液肺炎克雷伯菌分离株,用全基因组测序预测K与O血清型并行贝叶斯分层分析。估计20价K疫苗可覆盖72.9%感染(95%可信区间69.4%–76.5%),各区域≥70%;O型多样性较低,前5型覆盖86.2%。作者认为单一致20价K疫苗理论上可覆盖所有目标区域≥70%感染,但需进一步研究。

要点

  • 20价K疫苗(组合各区前8位K位点)估计覆盖72.9%感染,各区域≥70%。
  • O型多样性较低,前5型估计覆盖86.2%感染(各区76%–92%)。
  • 主要局限为依赖基因组序列预测血清型且缺乏纵向数据评估抗原稳定性。

核心结论

  • 新生儿败血症相关K与O型呈多样性,即使校正局部传播簇后仍存在显著地理与时间变异。
  • 单一致20价K疫苗理论上可覆盖所有目标区域≥70%感染。
  • 针对O抗原抗体的保护效力仍不确定,需进一步研究交叉反应性、抗原暴露及抗原随时间稳定性。

研究设计与样本

  • 分析13国35个监测点13项监测研究的1930株新生儿血液肺炎克雷伯菌分离株。
  • 采用病原全基因组测序预测K与O血清型并校正局部传播簇。
  • 采用贝叶斯分层Meta分析估计总体及各区域K与O流行率,以监测点为随机效应。

主要发现

  • 共鉴定87个K位点,KL2、KL102、KL25、KL15和KL62合计占49%分离株。
  • 估计20个K位点(组合各区前8位)可覆盖全部感染的72.9%(95%可信区间69.4%–76.5%),东非、西非、南部非洲和南亚各区域≥70%。
  • 三个监测点的初步发现提示K位点具足够时间稳定性以维持20价K疫苗覆盖5–10年,但需更多纵向数据支持该预测。
  • O型多样性远低于K型(n=14型);估计前5型(O1⍺β,2⍺、O1⍺β,2β、O2⍺、O2β和O4)覆盖全部感染的86.2%(95%可信区间82.6%–89.9%),各区76%–92%;前10型覆盖所有四区域约99%感染。

关键数值与推荐

  • 20价K疫苗覆盖估计:全部感染72.9%(95%可信区间69.4%–76.5%),各区域≥70%。
  • 前5位O型覆盖估计:全部感染86.2%(95%可信区间82.6%–89.9%),各区76%–92%。
  • 前10位O型覆盖所有四区域约99%感染。

临床怎么用

  • 作者认为单一致20价K疫苗理论上可覆盖所有目标区域≥70%感染。
  • 作者认为局部靶向疫苗可以更低价数实现更高覆盖,但可行性较低。
  • 作者指出基于O抗原的低价疫苗原则上可实现很高覆盖,但针对O抗原抗体的保护效力仍不确定。

局限性

  • 研究依赖基因组序列预测K与O血清型,因血清学分型不可用。
  • 缺乏纵向数据以探索抗原流行率随时间稳定性。
  • 需更多纵向数据支持20价K疫苗覆盖维持5–10年的预测。
  • 针对O抗原抗体的保护效力仍不确定。
  • 需进一步研究交叉反应性、抗原暴露及抗原随时间稳定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Klebsiella pneumoniae causes ~20% of sepsis in neonates, with ~40% crude mortality. A vaccine administered to pregnant women, protecting against ≥70% of K. pneumoniae infections, could avert ~400,000 cases and ~80,000 deaths annually, mostly in Africa and South Asia. Vaccine formulations targeting the capsular polysaccharide (K) or lipopolysaccharide (O) antigens are in development. Global K. pneumoniae populations display extensive K and O diversity, necessitating a polyvalent vaccine targeted to the serotypes associated with neonatal disease in relevant geographical regions. We investigated the prevalence of K and O types associated with neonatal sepsis in Africa and South Asia to inform maternal vaccine design. METHODS AND FINDINGS: We analysed 1,930 K. pneumoniae neonate blood isolates from 13 surveillance studies across 35 sites in 13 countries. We used pathogen whole-genome sequencing to predict K and O serotypes and adjust for local transmission clusters, and Bayesian hierarchical meta-analysis to estimate K and O prevalence overall and per region, treating site as a random effect. Eighty-seven K loci were identified. KL2, KL102, KL25, KL15, and KL62 accounted for 49% of isolates. We estimate that 20 K loci, combining the eight most prevalent per region, could cover 72.9% of all infections (95% credible interval: [69.4%, 76.5%]) and ≥70% in each of Eastern, Western, and Southern Africa and South Asia. Preliminary findings from three sites suggested sufficient temporal stability of K loci to maintain 20-valent K vaccine coverage over 5-10 years, but more longitudinal data are needed to support this prediction. O types were far less diverse (n = 14 types). We estimate the top-5 (O1⍺β,2⍺, O1⍺β,2β, O2⍺, O2β, and O4) would cover 86.2% [82.6, 89.9%] of total infections (76%-92% per region), while the top-10 would cover ~99% of infections in all four regions. The main limitations of our study are the reliance on genome sequences to predict K and O serotypes (as serological typing is not available) and a lack of longitudinal data to explore stability of antigen prevalence over time. CONCLUSIONS: Neonatal sepsis is associated with diverse K and O types, with substantial geographic and temporal variation even after adjusting for localised transmission clusters. Despite this, a single 20-valent K vaccine could theoretically cover ≥70% of infections in all target regions. Locally-targeted vaccines could achieve higher coverage with lower valency, but are less feasible. In principle, very high coverage could be achieved with lower valency O-based vaccines, however, the protective efficacy against disease of antibodies targeting the O antigen remains uncertain. Further research is needed on cross-reactivity, antigen exposure, and stability of antigens over time, to better inform vaccine development.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Stanton TD, Keegan SP, Abdulahi JA, et al. Distribution of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and South Asia: A meta-analysis of genome-predicted serotype prevalence to inform potential vaccine coverage. PLoS Med. 2026. PMID: 41525325. doi:10.1371/journal.pmed.1004879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。